

Summit Corporation plc
(‘Summit’ or the ‘Company’)

**SUMMIT TO PRESENT COMPANY OVERVIEW AT JMP SECURITIES
HEALTHCARE CONFERENCE**

Oxford, UK, 19 June 2014 – Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and *C. difficile* infection, announces that it will be presenting at the JMP Securities Healthcare Conference in New York on Wednesday, 25 June at 14:00 EST (19:00 BST).

Mr Glyn Edwards, Summit’s Chief Executive Officer, will present a review of the Company’s utrophin modulation programme for the treatment of the fatal muscle wasting disease DMD and he will also review Summit’s selective antibiotic in development for the treatment of CDI.

A copy of the presentation will be available immediately after the event on the Investor Relations section of the Company’s website, www.summitplc.com.

- END -

Notes to Editors

About Summit

Summit is an Oxford, UK based drug discovery and development company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and *C. difficile* infection. Summit is quoted on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and Summit can be followed on Twitter ([@summitplc](https://twitter.com/summitplc)).

For more information, please contact:

Summit

Glyn Edwards / Richard Pye

Tel: +44 (0)1235 443 951

Cairn Financial Advisers LLP

(Nominated Adviser)

Liam Murray / Tony Rawlinson

Tel: +44 (0)20 77148 7900

N+1 Singer

(Broker)

Aubrey Powell / Will Goode

Tel: +44 (0)20 7496 3000

Peckwater PR

(Financial public relations, UK)

Tarquin Edwards

Tel: +44 (0)7879 458 364

tarquin.edwards@peckwaterpr.co.uk

MacDougall Biomedical Communications

(US media contact)

Michelle Avery

Tel: +1 781 235 3060